The anti-migraine antibody erenumab is approved in the EU

Erenumab is a human IgG2 antibody that targets
the CGRP receptor (peptides bound to the calcitonin gene). This defines
the antibody is on a completely new approach in the prophylaxis of migraine and is
the first representative of a new class of drugs. By binding to the CGRP receiver
interaction with the natural ligand CGRP is inhibited. CGRP is a
Neuropeptide of 37 amino acids in the central and peripheral nervous system
is expressed. It has strong vasodilating properties and plays in the
The triggering pain as well as in the neurogenic inflammation a central role. at
Migraine sufferers can be found in an increased seizure of CGRP values. by
Intravenous administration of the peptide can even trigger seizures.
Triptans used in the acute treatment of the inhibition of migraine
including release of CGRP by acting as agonists on 5-HT1 receptors
act. In addition to reducing the release of CGRP, they lead to vasoconstriction,
inhibit nociceptive transmission (conduction of pain) and reduce secretion
other neuropeptides such as substance P.